Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection
- PMID: 17579921
- DOI: 10.1002/rmv.535
Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection
Abstract
We reviewed studies that reported results of systematic cytomegalovirus (CMV) screening on fetuses and/or live-born infants. The overall birth prevalence of congenital CMV infection was 0.64%, but varied considerably among different study populations. About 11% of live-born infants with congenital CMV infection were symptomatic, but the inter-study differences in definitions of symptomatic cases limit the interpretation of these data. Non-white race, low socioeconomic status (SES), premature birth, and neonatal intensive care unit admittance were risk factors for congenital CMV infection. Birth prevalence increased with maternal CMV seroprevalence. Maternal seroprevalence accounted for 29% of the variance in birth prevalence between study populations. Maternal seroprevalence and birth prevalence were both higher in study populations that were ascertained at birth rather than in the prenatal period. Thus, timing of ascertainment should be considered when interpreting birth prevalence estimates. Birth prevalence was inversely correlated with mean maternal age, but this relationship was not significant when controlling for maternal seroprevalence. The rate of transmission to infants born to mothers who had a primary infection or a recurrent infection during pregnancy was 32% and 1.4%, respectively. Possible maternal primary infections (i.e. seropositive mother with CMV IgM) resulted in congenital infections about 20% of the time, but are likely to represent a mixture of primary and recurrent infections. In summary, CMV is a common congenital infection worldwide that can lead to permanent disabilities. There is an urgent need for interventions that can reduce the substantial burden of this often overlooked disease.
Similar articles
-
CMV seroconversion in pregnants and the incidence of congenital CMV infection.Turk J Pediatr. 2007 Jan-Mar;49(1):30-6. Turk J Pediatr. 2007. PMID: 17479641
-
Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection.Rev Med Virol. 2010 Jul;20(4):202-13. doi: 10.1002/rmv.655. Rev Med Virol. 2010. PMID: 20564615 Review.
-
Perinatal or early-postnatal cytomegalovirus infection in preterm infants under 34 weeks gestation born to CMV-seropositive mothers within a high-seroprevalence population.J Pediatr. 2004 Nov;145(5):685-8. doi: 10.1016/j.jpeds.2004.07.025. J Pediatr. 2004. PMID: 15520780
-
Maternal antibodies against cytomegalovirus in pregnancy and the risk of fetal death and low birth weight.Acta Obstet Gynecol Scand. 2005 Nov;84(11):1035-41. doi: 10.1111/j.0001-6349.2005.00796.x. Acta Obstet Gynecol Scand. 2005. PMID: 16232169
-
Cytomegalovirus seroconversion rates and risk factors: implications for congenital CMV.Rev Med Virol. 2010 Sep;20(5):311-26. doi: 10.1002/rmv.659. Rev Med Virol. 2010. PMID: 20645278 Review.
Cited by
-
Newborn Screening for Congenital Cytomegalovirus (cCMV) Infection: Universal, Targeted, Expanded-Targeted, or None-of-the-Above?Neonatol Today. 2024 Aug;19(8):3-12. Neonatol Today. 2024. PMID: 39445079 Free PMC article.
-
Valganciclovir for symptomatic congenital cytomegalovirus disease.N Engl J Med. 2015 Mar 5;372(10):933-43. doi: 10.1056/NEJMoa1404599. N Engl J Med. 2015. PMID: 25738669 Free PMC article. Clinical Trial.
-
Risk factors associated with late-onset hearing loss in children with congenital cytomegalovirus: a systematic review.Eur Arch Otorhinolaryngol. 2024 Oct 4. doi: 10.1007/s00405-024-09013-0. Online ahead of print. Eur Arch Otorhinolaryngol. 2024. PMID: 39367221 Review.
-
CD8+ effector T cells at the fetal-maternal interface, balancing fetal tolerance and antiviral immunity.Am J Reprod Immunol. 2013 Apr;69(4):395-407. doi: 10.1111/aji.12094. Epub 2013 Feb 23. Am J Reprod Immunol. 2013. PMID: 23432707 Free PMC article. Review.
-
Using blood donors and solid organ transplant donors and recipients to estimate the seroprevalence of cytomegalovirus and Epstein-Barr virus in Canada: A cross-sectional study.J Assoc Med Microbiol Infect Dis Can. 2020 Oct 11;5(3):158-176. doi: 10.3138/jammi-2020-0005. eCollection 2020 Oct. J Assoc Med Microbiol Infect Dis Can. 2020. PMID: 36341316 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical